RaineA.E.G., MargreiterR., BrunnerF.P.Report on the management of renal failure in Europe. Nephrol Dial Transplant1991; 2: 7–35.
2.
VincentiF., AmendW.J., AbeleJ., FeduskaN.J., SalvatierraO.Jr.The role of hypertension in haemodialysis-associated atherosclerosis. Am J Med1980; 68(3): 363–9.
3.
NishizawaY., ShojiT., KawagishiT., MoriiH.Atherosclerosis in uremia: possible roles of hyperparathyroidsm and intermediate lipoprotein accumulation. Kidney Int1997; 62(Suppl): S90–2.
4.
AttmanP.O., AlaupovivP., GustafsonA.Lipid and apolipoprotein profiles of uraemic dyslipoproteinemia - relation to renal function and dialysis. Nephron1993; 57: 401–10.
5.
BagdadeJ.D.Hyperlipidemia and atherosclerosis in chronic dialysis patients. In: DrikkerW., ParsonsF.M., and MaherJ.F., eds. Replacement of renal function by dialysis.Boston, MA: Nijhoff Publishers, 1983; 588.
6.
RossR.The pathogenesis of atherosclerosis, a perspective for the 1990s. Nature1993; 362: 801–9.
7.
RubinK., HanssonG.K., RonnstrandL.Induction of B-type receptors for platelet derived growth factor in vascular inflammation: possible implication for development of vascular proliferative lesions. Lancet1988; 1: 1353–6.
8.
LibbyP., WarnerS.J.C., SalomonR.N., BirinyiL.K.Production of platelet-derived growth factor like mitogen by smooth-muscle cells from human atheroma. N Engl Med1988; 318: 1493–8.
BerkB., AlexanderR.W., BrockT.A., GimbroneM.A., WebbR.C.Vasoconstriction: A new activity for platelet-derived growth factor. Science1986; 232(4746): 87–90.
11.
NelsonP.R., YamamuraS., KentK.C.Platelet-derived growth factor and extracellular matrix proteins provide a synergistic stimulus for human vascular smooth muscle cell migration. J Vasc Surg1997; 26(1): 104–12.
12.
KaplanK.L., OwenJ.Plasma levels of beta-thromboglobulin and platelet factor 4 as indexes of platelet activation in vivo. Blood1981; 57: 199.
13.
FeedmanM.D.Pharmacodynamics, clinical indications and adverse effects of heparin. J Clin Pharmacol1992; 32(7): 584–96.
14.
MohammadS.F., AndersonW.H., SmithJ.B., ChuangH.Y., MasonR.G.Effects of heparin on platelet aggregation, release reaction and tromboxane A2 production. Am J Pathol1981; 104(2): 132–41.
15.
AndrassyK., RitzE., BommerJ.Effects of hemodialysis on platelets. Contrib Nephrol1987; 59: 26–34.
16.
MasonR.G., KimS.W., AndradeJ.D., HakimR.M.Blood surface interactions. Trans Am Soc Artif Intern Organs1980; 26: 603.
17.
ColìL., De SanctisL.B., FeliciangeliG.Dialysis membrane biocompatibility: effects on cellular elements. Nephrol Dial Transplant1995, 10: 27–32.
18.
LindsayR.M., RourkeJ.T.B., ReidB.D.The role of heparin on platelet retention by acrylonitrile co-polyper dialysis membranes. J Lab Clin Med1977; 89: 4.
19.
WindusD.W., AtkinsonR., SantoroS.The effects of hemodilysis on platelet activation with new and reprocessed regenerated cellulose dialyzers. Am J Kidney Dis1996; 27(3): 387–93.
20.
LimberG.K., MasauR.G.Studies of protein elutable from certain surfaces exposed to human plasma. Thromb Res1975; 6: 421–30.
21.
EdmundsL.H.Blood-surface interactions during cardiopulmonary by-pass. J Cardiac Surg1993; 8: 404–10.
22.
BoldtJ., ZickmannB., BensonM., DapperF., HempelmannG., SchindlerE.Does platelet size correlate with function in patients undergoing cardiac surgery?Intens Care Med1993; 19(1): 44–7.
23.
HoenichN.A.Platelet and leucocyte behaviour during haemodialysis. Contrib Nephrol1993; 19: 44–7.
24.
FlickerW., MilthorpeB.K., ScindheimK.Platelet factor release following heparin administration and during extracorporeal circulation. Trans Am Soc Artif Intern Organs1996; 28: 431–6.
25.
StemermanM.B.Vascular Injury: platelets and muscle cell response. Phil Trans R Soc Lond1981; 294: 217–24.
26.
BurdickL., PeritiM., SalvaggioA.Relation between carotid arthery atherosclerosis and time on dialysis. A non invasive study in vivo. Clin Nephrol1994; 42(2): 121–6.
27.
BommerJ., StrhobeckE., GoerichJ., BahnerM., ZunaI.Arteriosclerosis in dialysis patients. Int J Artif Organs1996; 19(11): 638–44.
28.
HaaberA.B., EidemakI., JensenT., Feldt-RasmussenB., StrandgaardS.Vascular endothelial cell function and cardiovascular risk factors in patients with chronic renal failure. J Am Soc Nephrol1995; 5(8): 1581–4.
29.
MaggiE., BellazziR., FalaschiF.Enhanced LDL oxidation in uremic patients: and additional mechanism for accelerated atherosclerosis?Kidney Int1994; 45(3): 876–83.
30.
WitzumJ.L., SteinbergD.Role of oxidized low density lipoprotein in atherogenesis. J Clin Invest1991; 88: 1785–92.
31.
ChauveauP., ChadefauxB., CoudeM.Hyperhomocysteinemia, a risk factor for atherosclerosis in chronic uremic patients. Kidney Int1993; 41(Suppl): S72–7.
32.
TeraokaJ., MatsuiN., NakagawaS., TakeuchiJ.The role of heparin in the changes of lipid pattern during a single hemodialysis. Clin Nephrol1985; 18: 135.
33.
KronenbergF., KathreinH., KonigP.Apolipoprotein(a) phenotypes predict the risk for carotid atherosclerosis in patients with end-stage renal disease. Arterioscler Thromb1994; 14(9): 1405–11.
34.
MatturriL., CazzulloA., TurconiP., LavezziA.M.Cytogenetic aspects of cell proliferation in atheroclerosis plaques. Cardiologia1997; 42(8): 883–6.
35.
GrafK., XiX.P., YangD., FleckE., HsuehW.A., LawR.E.Mitogen-activated protein kinase activation is involved in platelet-derived growth factor-direct migration by vascular smooth muscle cells. Hypertension1997; 29: 334–9.
36.
CapliceN.M., AroneyC.N., BettJ.H.Growth factors release into the coronary circulation after vascular injury promote proliferation of human vascular smooth muscle cells in culture. J Am Coll Cardiol1997; 29(7): 1536–41.
